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Poster Session I S243syndrome/secondary AML (5), Non-Hodgkin’s Lymphoma (4), or
CML (3). There were 22 males, 9 females, ages 2 – 17 yrs, median
11. Ten patients (pts) had previously undergone myeloablative ther-
apy and HSCT, 8 pts had comorbid conditions increasing their risk
for treatment failure. Stem cell sources included 16 unrelated donors
(URD), 13 matched sibs and 2 mis-matched relatives. 29 of 31 HSC
donations were from mobilized peripheral blood and 2 were marrow.
Graft-versus-host disease (GVHD) prophylaxis was cyclosporine A
(CsA) alone in 9 pts and CsA and mycophenolate in 22 pts. Median
time to an ANC .500/mcl was 18 days and unsupported platelet
count .20,000/mcl was (28 pts) 17 days, 7 pts required no platelet
support. One pt failed to engraft and 3 had secondary graft loss. 6
pts developed Grade III-IV acute GVHD, 14 of the 24 pts surviving
more than 100 days developed chronic GVHD (8 limited, 6 exten-
sive). 16 pts survive, 10 without disease relapse or progression.
100-day mortality (7 of 31, 23%) was from infection (3), GVHD
(3) and relapse (1). 8 of 19 pts with matched donors relapsed, 2
died of infections complicating GVHD whereas 3 of 12 pts with mis-
matched donors relapsed, 7 died of complications: infection, GVHD
or graft failure.
RFS for patients HLA-matched at the allele (8 of 8) level was 42%
vs 18% (p5 0.04) with$ 1 mismatch while Overall Survival was
64% vs 24% (p5 0.02). Our results suggest RIC allogeneic HSCT
should be considered for pediatric pts with hematologic malignan-
cies, especially if a well-matched (related or unrelated) donor can
be identified. Our current studies are focused on reducing the toxic-
ity for recipients of mismatched grafts.
Patient Characteristics (n5 31)
Age—yrs, (median, std dev) 11 1/- 4
M – F 22 – 9
Prior Autologous HSCT 6
Prior Allogeneic HSCT 4
Matched Sib HSC 13URD or mm Relative HSC 18
HSC Dose–CD341 cells/kg, x10e6 (median,
std dev)8.8 1/- 5.7229
OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
IN CHILDREN WITH CONGENITAL HEART DISEASE (CHD)
Guinan, E.C.1,2, Hewett, E.K.2, Domaney, N.M.2, Margossian, R.3
1Children’s Hospital, Boston, MA; 2Dana-Farber Cancer Institute, Bos-
ton, MA; 3Children’s Hospital, Boston, MA
CHD is the most common birth defect in the US. Improved sup-
portive care has resulted in more pediatric and adult survivors who
may develop indications for HSCT. We hypothesized there would
be overrepresentation of CHD in children undergoing HSCT, as
several inherited immune and bone marrow (BM) failure disorders
are associated with an increased CHD prevalence. As HSCT out-
comes of patients (pts) with CHD are not well known, we conducted
a retrospective chart review of 1185 sequential HSCT on 1031 pts
performed at Children’s Hospital Boston from 1989-2007. We
found 10 pts with major cardiac structural defects requiring surgical
catheterization or intervention for repair or palliation. Cardiac char-
acteristics are outlined in the table. 8 pts underwent allogeneic
HSCT for ALL (n5 4), AML (n5 1), CML (n5 1), Diamond-
Blackfan anemia (n5 1), and DiGeorge syndrome (n5 1) using
BM from matched sibling (n5 4) or unrelated donors (n5 3). 1 pt
received fresh T cells from a haploidentical donor. 2 pts underwent
autologous HSCT using BM for ALL (n5 1) and AML (n5 1).
Conditioning was cyclophosphamide (CY) and TBI +/- other che-
motherapy (n5 7) or CY +/- other chemotherapy (n5 2). The hap-
loidentical HSCT was performed without conditioning. GVHD
prophylaxis was cyclosporine and methotrexate, plus corticosteroids
for some unrelated BM recipients. Median time to absolute neutro-
phil count of 500/uL was 25 days (D, range 17-50). 2/8 allogeneic
HSCT recipients developed acute GVHD (1 Grade 2, 1 Grade 3).
1 received systemic corticosteroids. 50% of pts developed febrile
neutropenia. 2 had documented bacteremia, but no endocarditis or
life-threatening infectious toxicity was seen. Combined rates of
grade 3, 4, and 5 cardiac, pulmonary, and renal toxicities (NIH
CTC v. 3) through D + 100 were 10%, 10%, and 0%, respectively.
No pts died in the first 100 D post-HSCT. Pt follow-up ranged0.44-9.25 yrs (median 3.9yrs). 5 pts died at a median of 690D (range
159-780) of relapse (n5 4) and pulmonary hemorrhage (n5 1). 5 pts
underwent post-HSCT cardiac repair. 4 procedures were completed
uneventfully; 1 pt died of sepsis and pulmonary hemorrhage. Overall
CHD rates were 2-5  greater in our pts than US rates. We found
promising acute and long-term HSCT outcomes for children with
CHD, who readily tolerated HSCT associated volume challenges,
febrile neutropenia, and regimen-related toxicity, and suggest that
children with CHD should not be excluded from HSCT solely
due to their cardiac anomalies.
Cardiac Status on Admission
AgePatient
T
pat
rans-
lantCardiac
DiagnosisPrior
SurgeryPrior
AnthracyclineChronic
Cardiac
Rx1 2.5 Complex single
right ventricle
Bidirectional
Glenn shunt
No Enalapril,
aspirin2 5.3 Coarctation,
patent ductus
arteriosus
None Doxorubicin
60 mg/m2 1
dexrazoxane
None3 8.9 Truncus
Arteriosus Type
1A, ventricular
septal defect
Truncus repair No Enalapril4 13.9 Atrial septal
defect
None Daunorubicin
135 mg/m2
None5 0.3 Tetralogy of
Fallot
Tetralogy of
Fallot repair
No Digoxin6 8 Pulmonary
stenosis
Pulmonary
balloon
valvuloplasty
Doxorubicin
60 mg/m2
None7 10.6 Atrioventricular
canal defect
Atrioventricular
canal defect
repair
Doxorubicin* None8 18.5 Primum atrial
septal defect, cleft
mitral valve
None Daunorubicin
135 mg/m2
None9 1.5 Bicommissural
aortic valve,
coarctation,
mitral stenosis,
ventricular septal
defect
None Daunorubicin
128 mg/m2;
Idarubicin
30.6 mg/m2
None10 6.3 D-loop
transposition of
the great arteries,
ventricular septal
defect, pulmonary
stenosis
Blalock-Taussig
shunt, Rastelli
procedure,
conduit
revision,
pulmonary
valve
replacement
Doxorubicin
60 mg/m2 1
dexrazoxane
Aspirin*Initial care at outside institution, cannot confirm dose.230
RISK ADAPTED ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT)
FOR ACQUIRED SEVERE APLASTIC ANEMIA (SAA) IN PEDIATRIC RECIPI-
ENTS: IMPROVED OUTCOMES WITH UNRELATED DONORS
Mc Guinn, C.1, Geyer, M.B.1, Jacobson, J.S.2, Garvin, J.H.1,
Baldinger, L.1, van de Ven, C.1, Bhatia, M.1, Satwani, P.1,
Bradley, M.B.1, George, D.1, Schwartz, J.3, Morris, E.1, Hawks, R.1,
Foley, S.1, Baxter-Lowe, L.A.4, Cairo, M.S.1,3,5 1Morgan Stanley Child-
ren’s Hospital of New York Presbyterian, ColumbiaUniversity, NY; 2Her-
bert Irving Comprehensive Cancer Center, and Joseph L. Mailman School
of Public Health, Columbia University, New York, NY; 3Columbia Uni-
versity, New York, NY; 4University of California, San Francisco, CA;
5Columbia University, New York, NY
Background: AlloSCT from matched sibling donors (MSD) has re-
sulted in the highest survival rates in children and adolescents with
S244 Poster Session ISAA (Kobayashi et al, BJH, 2006). Previously, outcomes for alterna-
tive donor sources have been inferior secondary to higher rates of
graft rejection, GVHD and increased mortality (Bacigalupo et al,
Blood, 2000).
Objective:Given the poor outcome of medical therapy for SAA (Be-
kassy et al, PBC, 2005) and the improvements in HLA matching and
outcomes of transplants from alternative donor sources (Maury et al,
Haematologica, 2007), we investigated a risk-adapted AlloSCT ap-
proach in 22 consecutive patients.
Methods: Patients with\10 transfusions received reduced toxicity
conditioning: Cy 60 mg/kg + Flu 180 mg/m2 + rATG 8 mg/kg
(n5 10) or Bu 16 mg/kg + Flu 180 mg/m2 + Alemtuzumab 54 mg/
m2 (n5 3). 9 patients received myeloablative conditioning: Cy
200 mg/m2 + Flu 180 mg/m2 + rATG 8 mg/kg (n5 8) or Bu
16 mg/kg + Mel 135 mg/m2 + rATG 8 mg/kg (n5 1).
Results: M/F: 14/8, median age: 9.5 years (3-18yrs), median fol-
low-up: 19 months (1-85mos). Stem cell source: Well-MSD BM
(9 6/6, 3 5/6); PB (CD34 Selected) MUD (1 10/10, 2 9/10);
UCB (4 5/6, 3 4/6). All patients received Tacrolimus and myco-
phenolate mofetil as AGVHD prophylaxis (Osunkwo/Cairo et al,
BBMT, 2004). Median time to neutrophil and platelet engraft-
ment was 14 days (8-32 days) and 32.5 days (11-66 days), respec-
tively. 21 patients engrafted (95% CI: 77.2-99.9); 1 patient had
primary graft failure (4.5%). Day +100 mean chimerism was
96.4%, and patients did not differ by intensity of conditioning.
Among the 7 patients (31.8%) who developed grade 2-4
GVHD, risk was not associated with conditioning regimen, do-
nor source or HLA match. One-year OS was 71.6% (standard
error 9.8%, 95% CI 50.7-92.6%) and an association was not de-
tectable in regards to donor source, HLA disparity or condition-
ing intensity. Six patients died (27.3%) (multiorgan failure: 3,
extensive GVHD: 1, fungal infection: 1, TMA: 1). 3 patients
had secondary graft failure (16.6%) and 2 patients required a sec-
ond transplant secondary to adenovirus and pure red blood cell
aplasia. Our data suggest that a risk-adapted approach to Al-
loSCT from related and alternative donor sources is a feasible
strategy for treatment of newly diagnosed pediatric patients
with SAA.231
25-HYDROXY VITAMIN D DEFICIENCY IN PEDIATRIC PATIENTS FOL-
LOWING HEMATOPOIETIC STEM CELL TRANSPLANT
Apfelbaum, E.1, Vrooman, L.M.1, Lehmann, L.E.1, Bechard, L.J.2,
Duncan, C.N.1 1Dana-Farber Cancer Institute, Boston, MA; 2Children’s
Hospital, Boston, MA
Pediatric patients following hematopoietic stem cell transplant
(HSCT) are at increased risk for vitamin D deficiency due to
lack of sun exposure and sunscreen use, some medications, and
dietary insufficiency. We investigated the incidence of 25-OH vi-
tamin D deficiency in pediatric patients following HSCT. The
study population included 90 patients (52 male, 38 female). 11
subjects had autologous HSCTs and 79 received allogeneic
HSCTs. The median time from transplant was 177 days (range
13-6873 days). 76% of subjects were Caucasian, 8% Hispanic,
7% Asian, 5% African American, and 4% mixed ethnicity. The
underlying diseases were ALL (27.8%), AML/MDS (20%), non-
malignant hematologic disorder (18.9%), solid tumor (12.3%),
immunodeficiency (7.8%), CML (4.4%), lymphoma (4.4%), and
other disorder (4.4%). 27.8% of patients received corticosteroids
and 51.1% took calcineurin inhibitors at the time of enrollment.
At enrollment, 5 patients received multivitamins and 4 patients
took vitamin D supplements. The incidence of 25-OH vitamin
D insufficiency, defined as a level less than 30 ng/mL, was
87%. 53% of patients were deficient with levels less than 20
ng/mL. The median 25-OH vitamin D level was 18 ng/mL
(mean 21.1 ng/mL). Patients with deficiency were prescribed
50,000 IU of ergocalciferol orally once weekly for 6 weeks. 47 pa-
tients received supplementation and post-supplementation values
were available for 40 patients. 5 patients died prior to repeat test-
ing and levels were missing for 2 patients. Repeat post-supple-
mentation testing revealed a median level of 30 ng/mL. 12.5%(n5 5) of those supplemented remained deficient 20 ng/mL and
47.5% (n5 19) remained insufficient. This study highlights the
need to monitor pediatric patients for vitamin D deficiency. A
better understanding of the risk factors and appropriate treatment
for vitamin D deficiency following HSCT is needed.232
BUSULFAN + FLUDARABINE, AN EFFECTIVE AND LOW TOXIC REGIMEN
IN CHILDREN WITH MALIGNANT AND NON-MALIGNANT DISEASES
Flinsenberg, T.W.H.1, Bartelink, I.H.2, Ververs, T.F.T.T.2,
Bierings, M.1, Boelens, J.J.1 1UMCU, Utrecht, Netherlands; 2UMCU,
Utrecht, Netherlands
Background: Busulfan as myeloablative agent is used in condition-
ing prior to pediatric HSCT: mainly in combination with cyclophos-
phomide. We recently found a clear association between busulfan
exposure and outcomes (survival/event free survival). However, tox-
icity leading to morbidity and associated mortality remains a limiting
factor. Comparison studies in adults showed a favorable toxicity pro-
file for fludarabine + busulfan (FludBu) compared to the conven-
tional BuCy regimen. In paediatrics, limited data is available
regarding this regimen. FludBu was recently introduced to replace
the BuCy regimen in our center for myeloid malignancies and all
non-malignant indications. We compared the outcomes with our
BuCy historic controls.
Methods: Fludarabine was given in 1 hour prior to a 3 hour infusion
of once daily busulfan. The target area under the curve (AUC) for Bu
was. 74 mg*h/L (in total) in both groups. Busulfan dose targeting,
based on therapeutic drug monitoring was performed before the sec-
ond dose. Primary endpoints were event free survival (EFS) and sur-
vival. Secondary endpoints were acute graft-versus-host disease
(aGvHD), neutropenic period and the number of erythrocytes and
thrombocytes transfusions. A risk factor analysis was performed us-
ing univariable and multivariable COX regression.
Results: 13 patients were included in the FludBu group (median
follow up median 119 days; range 42-1593) and 44 in the BuCy
group (710 days; range 6-1686). The groups were comparable re-
garding donor source, age, gender, indication for SCT and match-
grade. EFS and Survival in FludBu and BuCy was 85% vs 71%
(NS) and 92% vs. 73% (NS), respectively. No difference in
aGvHD ($grade 2) was found between the 2 groups. The period
of neutropenia was median 12 in the FludBu group compared to
20.5 in the BuCy group (HR 0.38, p5 0.05, CI95% 0.20-0.75).
The median number of erythrocytes transfusion was 1 (range 1-
13) in the FludBu group and 5 (0-22) in the BuCy group
(p5 0.20) and thrombocyte infusions 5 (range 0-33) vs 10 (range
2-44)(p5 0,15).
Conclusions: Busulfan with a total target AUC of .74 mg*h/l in
combination fludarabine showed to be an effective and low toxic reg-
imen. Interesting is the significantly shorter neutropenic period and
lower number of transfusions (erythrocytes and thrombocytes)
needed in the FludBu group in comparison to BuCy. Although
a small series, FludBu showed promising results. Further follow up
and extension of the series is needed.233
PERI-TRANSPLANT INFECTIONS IN UNRELATED CORD BLOOD TRANS-
PLANTATION AND THEIR INFLUENCE ON OUTCOME
Alsultan, A., Giller, R.H., Gao, D., Bathurst, J., Hild, E.,
Foreman, N.K., Keating, A., Quinones, R.R. The Children’s Hospital
and University of Colorado Denver, Aurora, CO
Infection in the peri-transplant period is a major cause of
morbidity and mortality post-transplant. The nature of peri-
transplant infections and their influence on outcome post unre-
lated cord blood transplant (UCBT) need to be further eluci-
dated.
Methods: We reviewed peri-transplant infections in 81 consecutive
UCBT. All culture-documented infections were reviewed starting 3
months pre-transplant through the first 100 days post-transplant.
Acute GVHD (aGVHD) II-IV, aGVHD III-IV, chronic GVHD
(cGVHD), and event free survival (EFS) were used as endpoints.
